vs

Side-by-side financial comparison of FIRST NATIONAL CORP (FXNC) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $24.0M, roughly 1.5× FIRST NATIONAL CORP). FIRST NATIONAL CORP runs the higher net margin — 23.0% vs -304.2%, a 327.2% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs -3.4%). FIRST NATIONAL CORP produced more free cash flow last quarter ($20.9M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 26.8%).

VA Tech Wabag Ltd. is an Indian multinational company focussed on desalination and water treatment for municipal and industrial users. Founded in Breslau in 1924, the company is headquartered in Chennai.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

FXNC vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.5× larger
RXRX
$35.5M
$24.0M
FXNC
Growing faster (revenue YoY)
RXRX
RXRX
+685.1% gap
RXRX
681.7%
-3.4%
FXNC
Higher net margin
FXNC
FXNC
327.2% more per $
FXNC
23.0%
-304.2%
RXRX
More free cash flow
FXNC
FXNC
$68.2M more FCF
FXNC
$20.9M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
26.8%
FXNC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FXNC
FXNC
RXRX
RXRX
Revenue
$24.0M
$35.5M
Net Profit
$5.5M
$-108.1M
Gross Margin
59.8%
Operating Margin
28.8%
-304.8%
Net Margin
23.0%
-304.2%
Revenue YoY
-3.4%
681.7%
Net Profit YoY
689.9%
39.6%
EPS (diluted)
$0.60
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FXNC
FXNC
RXRX
RXRX
Q4 25
$24.0M
$35.5M
Q3 25
$22.8M
$5.2M
Q2 25
$22.4M
$19.2M
Q1 25
$21.1M
$14.7M
Q4 24
$24.8M
$4.5M
Q3 24
$15.0M
$26.1M
Q2 24
$14.2M
$14.4M
Q1 24
$14.9M
$13.8M
Net Profit
FXNC
FXNC
RXRX
RXRX
Q4 25
$5.5M
$-108.1M
Q3 25
$5.5M
$-162.3M
Q2 25
$5.1M
$-171.9M
Q1 25
$1.6M
$-202.5M
Q4 24
$-933.0K
$-178.9M
Q3 24
$2.2M
$-95.8M
Q2 24
$2.4M
$-97.5M
Q1 24
$3.2M
$-91.4M
Gross Margin
FXNC
FXNC
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
FXNC
FXNC
RXRX
RXRX
Q4 25
28.8%
-304.8%
Q3 25
29.9%
-3327.6%
Q2 25
28.2%
-916.8%
Q1 25
9.0%
-1297.9%
Q4 24
-29.0%
-4042.4%
Q3 24
18.7%
-377.1%
Q2 24
22.0%
-697.4%
Q1 24
26.9%
-698.4%
Net Margin
FXNC
FXNC
RXRX
RXRX
Q4 25
23.0%
-304.2%
Q3 25
24.3%
-3135.3%
Q2 25
22.5%
-894.2%
Q1 25
7.6%
-1373.3%
Q4 24
-14.4%
-3935.5%
Q3 24
15.0%
-367.5%
Q2 24
17.2%
-676.6%
Q1 24
21.5%
-662.4%
EPS (diluted)
FXNC
FXNC
RXRX
RXRX
Q4 25
$0.60
$-0.17
Q3 25
$0.62
$-0.36
Q2 25
$0.56
$-0.41
Q1 25
$0.18
$-0.50
Q4 24
$-0.26
$-0.56
Q3 24
$0.36
$-0.34
Q2 24
$0.39
$-0.40
Q1 24
$0.51
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FXNC
FXNC
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$160.9M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$186.2M
$1.1B
Total Assets
$2.0B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FXNC
FXNC
RXRX
RXRX
Q4 25
$160.9M
$743.3M
Q3 25
$189.3M
$659.8M
Q2 25
$194.3M
$525.1M
Q1 25
$206.0M
$500.5M
Q4 24
$162.9M
$594.4M
Q3 24
$126.5M
$427.6M
Q2 24
$135.6M
$474.3M
Q1 24
$296.3M
Total Debt
FXNC
FXNC
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
FXNC
FXNC
RXRX
RXRX
Q4 25
$186.2M
$1.1B
Q3 25
$181.2M
$1.0B
Q2 25
$173.5M
$919.1M
Q1 25
$168.7M
$933.9M
Q4 24
$166.5M
$1.0B
Q3 24
$125.1M
$524.6M
Q2 24
$119.9M
$584.4M
Q1 24
$117.8M
$401.2M
Total Assets
FXNC
FXNC
RXRX
RXRX
Q4 25
$2.0B
$1.5B
Q3 25
$2.0B
$1.4B
Q2 25
$2.0B
$1.3B
Q1 25
$2.0B
$1.3B
Q4 24
$2.0B
$1.4B
Q3 24
$1.5B
$726.5M
Q2 24
$1.5B
$775.9M
Q1 24
$1.4B
$557.8M
Debt / Equity
FXNC
FXNC
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FXNC
FXNC
RXRX
RXRX
Operating Cash FlowLast quarter
$25.1M
$-46.1M
Free Cash FlowOCF − Capex
$20.9M
$-47.3M
FCF MarginFCF / Revenue
87.3%
-133.1%
Capex IntensityCapex / Revenue
17.4%
3.5%
Cash ConversionOCF / Net Profit
4.56×
TTM Free Cash FlowTrailing 4 quarters
$34.9M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FXNC
FXNC
RXRX
RXRX
Q4 25
$25.1M
$-46.1M
Q3 25
$8.4M
$-117.4M
Q2 25
$4.7M
$-76.4M
Q1 25
$3.5M
$-132.0M
Q4 24
$-22.2M
$-115.4M
Q3 24
$6.1M
$-59.2M
Q2 24
$3.6M
$-82.2M
Q1 24
$4.7M
$-102.3M
Free Cash Flow
FXNC
FXNC
RXRX
RXRX
Q4 25
$20.9M
$-47.3M
Q3 25
$6.8M
$-117.6M
Q2 25
$4.1M
$-79.6M
Q1 25
$3.0M
$-133.8M
Q4 24
$-25.5M
$-116.7M
Q3 24
$4.9M
$-63.8M
Q2 24
$3.0M
$-83.4M
Q1 24
$4.4M
$-109.0M
FCF Margin
FXNC
FXNC
RXRX
RXRX
Q4 25
87.3%
-133.1%
Q3 25
30.0%
-2272.5%
Q2 25
18.3%
-413.9%
Q1 25
14.5%
-907.4%
Q4 24
-102.8%
-2567.7%
Q3 24
33.0%
-244.6%
Q2 24
21.0%
-578.5%
Q1 24
29.5%
-789.9%
Capex Intensity
FXNC
FXNC
RXRX
RXRX
Q4 25
17.4%
3.5%
Q3 25
7.0%
4.7%
Q2 25
2.6%
16.4%
Q1 25
2.3%
12.4%
Q4 24
13.3%
28.6%
Q3 24
8.1%
17.5%
Q2 24
4.6%
8.2%
Q1 24
2.0%
48.2%
Cash Conversion
FXNC
FXNC
RXRX
RXRX
Q4 25
4.56×
Q3 25
1.52×
Q2 25
0.93×
Q1 25
2.21×
Q4 24
Q3 24
2.73×
Q2 24
1.49×
Q1 24
1.47×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons